CALC

1.2607.69%
AJ

Allan J. Lee Shaw

Independent Director

Mr. Allan J. Lee Shaw, C.P.A. was CFO & Chief Business Officer of CREATE Medicines, Inc. from October 2025 to March 2026. Mr. Shaw is Director of Evecxia Therapeutics, Inc. from October 2023. He serves as Chief Business Officer and Chief Financial Officer since October 2025 at CREATE Medicines. He is Director of Graybug Vision, Inc. from February 5, 2023. He was the Chief Financial Officer at Portage Biotech Inc. since May 12, 2020 until September 30, 2024. He serves as Director at CalciMedica, Inc. since October 2021. He has served on five public boards and also a five-time public company Chief Financial Officer. He served as Chief Financial Officer at Sirnaomics, Inc. since May 28, 2019. He served as a Director of VIVUS Inc. since September 15, 2015 until October 23, 2019. He served as Consultant at VIVUS Inc. from February 1, 2018 to June 30, 2018. Mr. Shaw serves as Chief Financial Officer of ImmunoMet Therapeutics, Inc. since February 2018. Mr. Shaw served as Chief Financial Officer, Treasurer and Secretary at Syndax Pharmaceuticals, Inc. from January 20, 2016 to February 13, 2017. He served as Managing Director of New York Operations at Alvarez & Marsal, LLC since December 2011 to September 2015 and led A&M's biopharmaceutical consulting practice from December 2011 to March 2015. He served as Chief Financial Officer of NewLead Holdings Limited from October 13, 2009 to July 11, 2011 and its Principal Accounting Officer until July 11, 2011. He founded Shaw Strategic Capital LLC in 2005 and served as its Senior Managing Director from 2005 to 2009. He served as the Chief Financial Officer and Executive Management Board Member at Serono International S.A., from November 11, 2002 to May 2004. He served as an Executive Director of NewLead Holdings Limited from October 13, 2009 to July 2011. He served as Chief Financial Officer of Merck Serono S.A. from November 11, 2002 to May 2004. He served as the Chief Financial Officer of Serono S.A. from November 11, 2002 to 2004. Mr. Shaw served as the Chief Financial Officer of Viatel Holding (Bermuda) Ltd. from November 1994 to June 2002. He served as a Treasurer of Viatel from September 1996 to April 1998 and as its Corporate Controller from November 1994 to December 1995. From August 1987 to November 1994, he was employed by Deloitte & Touche LLP, as a Manager. He served as Managing Director with Deloitte & Touche. He served as a strategic adviser for international investment bank. He has extensive corporate governance and executive, financial leadership and management, operational and strategic perspective experience. He serves as a Director of Edith & Carl Marks JCH of Bensonhurst. He serves as an Independent Director of OncoHoldings, Inc. He served as a Director of Akari Therapeutics, Plc until June 29, 2016. He served as Director of Celsus Therapeutics Plc since October 2, 2013. Mr. Shaw served as Independent Director of Navios Maritime Holdings Inc., from October 25, 2005 to July 2010. He served as a Member of the Board of Directors for the Central New York Biotech Accelerator (formerly Central New York-Biotech Research Center) from 2009 to 2013. He served as a Director of Viatel Holding (Bermuda) Ltd. (Formerly Vialtal Inc.) from June 1996 to June 2002. He had been Independent Director of Blue Water Vaccines, Inc. since January 2020 until August 22, 2022. He serves as Member of Corporate Directors Group. He serves as a Member of the American Institute and New York State Society of Certified Public Accountants. He is a Certified Public Accountant of the State of New York as well as a Chartered Global Management Accountant (CGMA). Mr. Shaw holds a BS in Applied Science and Accounting from the State University of New York (Oswego College) in 1986.

Positions